Evidence map›Paper›PMID 38903989›Full record

ArticleFrontiers in pharmacology2024

Molecular mechanism of the treatment of lung adenocarcinoma by

Sheng Wang, Na Yin, Yingyue Li, Zhaohang Ma, Wei Lin, Lihong Zhang, Yun Cui, Jianan Xia, Liang Geng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Investigation of the Anti-Lung Cancer Mechanisms ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sheng Wang *The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Na Yin *School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
Yingyue LiMedical Engineering Technology and Data Mining Institute, Zhengzhou University, Zhengzhou, China.
Zhaohang MaSchool of Computer Science and Technology, Beijing Jiaotong University, Beijing, China.
Wei LinSchool of Computer Science and Technology, Beijing Jiaotong University, Beijing, China.
Lihong ZhangThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Yun CuiThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Jianan XiaSchool of Computer Science and Technology, Beijing Jiaotong University, Beijing, China.
Liang GengThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: With a variety of active ingredients, Methods: Phenotype-genotype and herbal-target associations were extracted from the SymMap database. Disease-gene associations were extracted from the MalaCards database. A molecular network-based correlation analysis was further conducted on the collection of genes associated with TCM and the collection of genes associated with diseases and symptoms. Then, the network separation S Results: Included in the study were 85,437 electronic medical records (318 patients with LUAD). The proportion of prescriptions containing Conclusion:

Indexed as

complex networkCTNNB1Hedyotis diffusalung adenocarcinomareal world study

Identifiers

PMID38903989
PMCPMC11187350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.